283 related articles for article (PubMed ID: 21500870)
1. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.
Beresford MW
Paediatr Drugs; 2011 Jun; 13(3):161-73. PubMed ID: 21500870
[TBL] [Abstract][Full Text] [Related]
2. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
4. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
Beresford MW; Baildam EM
Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
[TBL] [Abstract][Full Text] [Related]
5. New advances in the management of juvenile idiopathic arthritis--1: non-biological therapy.
Beresford MW; Baildam EM
Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):144-50. PubMed ID: 19770494
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
7. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
Shenoi S; Wallace CA
Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
10. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
11. Recent therapeutic advances in juvenile idiopathic arthritis.
Giancane G; Alongi A; Rosina S; Tibaldi J; Consolaro A; Ravelli A
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):476-487. PubMed ID: 29773268
[TBL] [Abstract][Full Text] [Related]
12. [Biologic response modifiers for juvenile idiopathic arthritis].
Yokota S
Nihon Rinsho; 2007 Jul; 65(7):1331-5. PubMed ID: 17642252
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
[TBL] [Abstract][Full Text] [Related]
14. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
[TBL] [Abstract][Full Text] [Related]
15. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM
J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for treating juvenile idiopathic arthritis.
Turnier JL; Brunner HI
Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
[TBL] [Abstract][Full Text] [Related]
19. Juvenile idiopathic arthritis-associated uveitis.
Sen ES; Ramanan AV
Clin Immunol; 2020 Feb; 211():108322. PubMed ID: 31830532
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate for treating juvenile idiopathic arthritis.
Takken T; Van Der Net J; Helders PJ
Cochrane Database Syst Rev; 2001; (4):CD003129. PubMed ID: 11687174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
